Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2001 Sep:69:351-4.

[Effects of estrogens and progestogens on the lipid profile in postmenopausal hypogonadism]

[Article in Spanish]
Affiliations
  • PMID: 11816532
Clinical Trial

[Effects of estrogens and progestogens on the lipid profile in postmenopausal hypogonadism]

[Article in Spanish]
L García et al. Ginecol Obstet Mex. 2001 Sep.

Abstract

It is known that postmenopausal hypogonadism is associated to an increase of low density lipoproteins (LDL) and a decrease of high density lipoproteins (HDL) that increases the risk of cardiovascular disease. The hormonal replacement therapy of estrogen with or without a progestin reduces such risk in approximately 50%. This study of a retrospective clinical design was longitudinal, descriptive and comparative of 172 patient grouped for treatment received: a) with estrogen and progestin (E + P: 59.1%, n = 122), and b) estrogen alone (E: 40.9%, n = 50), in whom was determined: lipid profile and aterogenic risk initially and each year until 5 years of follow up. Results obtained were: 172 with average age of 51.5 +/- SD 9.2 years with average 5.5 duration years of postmenopause, in both groups the aterogenic risk was reduced as well as concentrations of serum LDL, while HDL increased. It is concluded that hormonal replacement therapy exerted a substantial effect upon main lipoproteins (HDL, LDL) modifying sensitively the aterogenic risk and consequently ameliorating the risk of cardiovascular disease and atherosclerosis.

PubMed Disclaimer